Skip to content

HIGH ALTITUDE CARDIOVASCULAR RESEARCH IN THE ANDES

HIGH ALTITUDE CARDIOVASCULAR RESEARCH IN THE ANDES

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
REPEC
Registry ID
PER-011-12
Enrollment
100
Registered
2012-04-12
Start date
2012-05-02
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

INSTITUTO AUXOLOGICO ITALIANO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) LOWLANDERS STUDY - MALE AND FEMALE SUBJECTS AGED 18-65 YEARS - PERMANENT RESIDENT AT LOW (<500 M) ALTITUDE - CONVENTIONAL SYSTOLIC BP (AVERAGE OF 2 MEASUREMENTS) 140-159 MMHG OR CONVENTIONAL DIASTOLIC BP 90-99 MMHG IN SUBJECTS UNTREATED OR AFTER 4 WEEKS OF WASHOUT - MEAN DAYTIME SYSTOLIC BP =135 AND <150 MMHG AND/OR MEAN DAYTIME DIASTOLIC BP =85 AND <95 MMHG IN SUBJECTS UNTREATED OR AFTER 4 WEEKS OF WASHOUT - WRITTEN INFORMED CONSENT TO PARTICIPATE IN THE STUDY. 2) HIGHLANDERS STUDY: - MALE AN FEMALE SUBJECTS AGED 18-65 YEARS WITHOUT CARE OF THEIR BLOOD PRESSURE STATUS - WRITTEN INFORMED CONSENT TO PARTICIPATE IN THE STUDY - PERMANENT RESIDENCE AT ALTITUDE ABOVE 4000 M.

Exclusion criteria

Exclusion criteria: 1) LOWLANDERS STUDY - CONVENTIONAL SYSTOLIC BP (AVERAGE OF 2 MEASUREMENTS) =150 MMHG AND CONVENTIONAL DIASTOLIC BP =95 MMHG IN TREATED SUBJECTS - REGULAR USE OF 2 OR MORE ANTIHYPERTENSIVE DRUGS (WITH THE EXCEPTION OF SUBJECTS ON 2 ANTYHYPERTENSIVE DRUGS IN LOW DOSES) - TREATED ANTIHYPERTENSIVE SUBJECTS IN WHOM WITHDRAWAL OF TREATMENT IS DEEMED UNETHICAL BY THE INVESTIGATOR (EG BECAUSE OF THE EXISTENCE OF COMPELLING INDICATIONS OTHER THAN HYPERTENSION FOR CONTINUOUS USE OF PEVIOUSLY USED ANTIHYPERTENSIVE AGENT) - CONTRAINDICATIONS (INCLUDING A HISTORY OF ADVERSE REACTIONS) TO ANGIOTENSIN RECEPTOR BLOCKERS OR CALCIUM ANTAGONISTS. - HISTORY OF SERIOUS MOUNTAIN SICKNESS - SUBJECTS WHO OVER 3 MONTHS PRECEDING INCLUSION IN THE STUDY SPENT CONSIDERABLE (>1 WEEK) AMOUNT OF TIME AT ALTITUDES ABOVE 2500 M. - CARDIOVASCULAR DISEASES OTHER THAN HYPERTENSION (CORONARY HEART DISEASE, HEART FAILURE, ATRIAL FIBRILLATION, VALVULAR OR CONGENITAL HEART DISEASE, CARDIOMYOPATHIES, CEREBROVASCULAR DISEASE, PERIPHERAL ARTERY DISEASE, AORTIC ANEURYSM) - SUSPECTED OR CONFIRMED SECONDARY HYPERTENSION - DIABETES MELLITUS - SERIOUS RESPIRATORY DISORDERS - OTHER CONDITIONS DEEMED RELEVANT BY THE INVESTIGATOR (INCLUDING LIVER DISEASE, RENAL DISEASE, THYROID DISORDERS) - BMI =35 KG/M2 - UPPER ARM CIRCUMFERENCE >32 CM - KNOWN SEVERE OBSTRUCTIVE SLEEP APNEA (APNEA-HYPOPNEA INDEX >30 OR USE OF CPAP) OR EXCESSIVE DAYTIME SLEEPINESS (EPWORTH SLEEPINESS SCALE >10) - PREGNANCY - PREMENOPAUSAL WO

Countries

Peru

Outcome results

None listed

Source: REPEC (via WHO ICTRP) · Data processed: Apr 4, 2026